Articles tagged with Brain Cancer
The proton therapy cohort of NRG-BN001 demonstrated improved overall survival (OS) for patients with newly diagnosed glioblastoma, with a 6.8% absolute survival advantage at 2 years. The results support the development of a phase III randomized trial to confirm these findings.
A new study decodes the mechanism of glioblastoma's resistance to chemotherapy by identifying a HIF-independent circuit built around the epigenetic enzyme PRMT2. Researchers found that combining an existing orphan drug with standard chemotherapy can overcome this resistance, doubling survival without added toxicity.
Virginia Tech researchers create method combining MRI, fluid dynamics, and algorithm to identify hidden glioblastoma cells. The technique uses fluid flow patterns to predict tumor re-growth, allowing for more aggressive surgical approaches. This technology has potential to improve cancer treatment outcomes
A team of scientists has identified rogue DNA rings as early drivers of glioblastoma growth, suggesting a window of opportunity for earlier detection and treatment. The study suggests that targeting these DNA rings could lead to more effective treatments.
Researchers have identified a potential new strategy for treating glioblastoma multiforme (GBM), the most common and aggressive type of adult brain cancer. Disabling a protein called ADAR1 can stall GBM cell proliferation while reprogramming the tumor microenvironment to an anti-tumoral state.
Researchers at the University of Mississippi have developed a new method to deliver cancer therapies directly to triple-negative breast cancer cells. The sugar-coated nanoparticles effectively target this aggressive cancer, which affects young women and disproportionately impacts Black women. The discovery holds promise for treating no...
Scientists have found a way to stop brain cancer cells from spreading by 'freezing' hyaluronic acid molecules in place. This approach could lead to a new type of treatment for glioblastoma, the most aggressive form of brain cancer.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers developed a multi-analyte test that accurately identifies brain cancers using small samples of cerebrospinal fluid, offering a promising new tool for guiding clinical decision-making. The test combines multiple biological markers and demonstrates high sensitivity and specificity in detecting central nervous system cancers.
Researchers achieved global-first using Brain Perioperative platform to learn how new drug suppresses tumour activity in low-grade gliomas, a slow-growing type of brain cancer. The trial involved patients who took the drug prior to any other cancer treatment and showed promising results.
The Ellen Siow Professorship aims to advance education and research in neuro-oncology, specifically glioblastoma. This will drive the development of innovative programmes and interventions, fostering progress that benefits people in Singapore and beyond.
Researchers at UCL discovered that blocking brain damage triggered by glioblastomas can slow cancer growth and maintain normal brain function. The study found that early-stage tumours damaged axons, accelerating tumor growth, but deactivating SARM1 slowed tumor progression.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
The expansion of Huntsman Cancer Institute's proton therapy center will double treatment capacity and increase access to life-saving cancer care for patients in Utah, Idaho, Montana, Nevada, and Wyoming. The new center will enable the treatment of more patients and expand proton therapy options for certain types of cancers.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
Hollings researchers use natural language processing to identify primary cancer types in medical notes, improving treatment accuracy and personalized care. The AI model achieves high accuracy rates, outperforming standard medical codes in identifying primary cancer diagnoses.
The Josep Carreras Leukaemia Research Institute is launching a joint research programme on childhood leukaemia, aiming to develop common strategies and improve treatments for the disease. Paediatric leukaemia remains a significant challenge due to its low incidence and high mortality rate.
An international research team has identified three key genes involved in controlling the invasion routes of glioblastoma. The study found that targeting these genes may lead to a potential new treatment strategy for the aggressive brain tumor.
Researchers Sontheimer and Monje have made groundbreaking discoveries in brain tumor growth, revealing how nerve cells promote the development of aggressive gliomas. Their work has laid the foundation for new treatments and clinical trials, offering hope for innovative therapies.
Researchers identified key factors behind a successful immunotherapy response in a young patient with rhabdoid tumour. The study highlights the potential of sequencing technologies to track immune cell profiles and develops personalized cell therapies.
Researchers at Mass General Brigham found that targeted radiation was successful in treating patients with brain metastases, resulting in a lower neurological death rate and reduced need for subsequent whole brain radiation. This study supports personalized treatment approaches to maintain quality of life while managing brain metastases.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
Researchers highlight the benefits of artificial intelligence in glioblastoma management, including improved diagnosis, treatment planning, and personalized therapy. AI-based models can analyze radiological images, predict tumor characteristics, and suggest effective treatments, promising to improve patient outcomes and survival rates.
Researchers developed a technique to measure brain tumors' mechanical force, distinguishing between tumors that push against the brain or invade surrounding tissue. This measurement can help clinicians inform patient strategies to alleviate symptoms and predict outcomes of chemotherapy and immunotherapy.
A new cytokine delivery platform reprograms the tumor microenvironment to enhance CAR-T cell function in preclinical brain cancer models. The strategy leads to a broader immune response that inhibits tumor growth and extends host survival, even in mice with only a fraction of cells expressing the CAR-targeted antigen.
Researchers at Florida Atlantic University have secured two key grants to investigate targeting the MBLAC1 gene as a new approach to treat glioblastoma, a very aggressive and fast-growing type of brain cancer. The project aims to advance innovative projects that could make a meaningful impact on cancer therapy.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
Sylvester researchers found that alcohol-related cancer deaths increased by nearly double from 1990 to 2021, primarily affecting men over 55. A new four-drug combination has been shown to be highly effective and safe in treating patients with newly diagnosed multiple myeloma.
A new molecule called the 'Fusion Superkine' has been created to target and kill glioblastoma cells while stimulating an immune response to prevent recurrence. The treatment, developed by VCU Massey Comprehensive Cancer Center researchers, uses a combination of immunotherapy and targeted delivery to overcome the blood-brain barrier and...
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
Researchers at Virginia Tech's Fralin Biomedical Research Institute are developing more precise treatments for pediatric brain cancer, specifically glioblastoma, by targeting cancer cells while sparing healthy tissue. The new therapies aim to deliver compounds more effectively to tumor sites using low-intensity focused ultrasound.
A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
Scientists at Terasaki Institute engineer a novel 3D glioblastoma model that mimics brain tissue and pericyte role, showing increased resistance to chemotherapy. The model increases sensitivity of GBM cell lines to TMZ by 22-32%.
Researchers at Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children. Targeting FGFR and NOTCH receptors may represent a critical vulnerability in ETMR.
A rare form of childhood brain cancer called Diffuse Midline Glioma (DMG) hijacks gene control machinery to fuel its growth. A specific gene-silencing complex, CBX4/PCGF4-cPRC1, is essential for tumour growth and could be a promising drug target.
A new ultra-rapid genetic test has been developed to diagnose brain tumors in under two hours, cutting the current wait time of 6-8 weeks. The test uses Oxford Nanopore Technologies portable sequencing devices and achieves a 100% success rate.
A new protein target has been identified for treating childhood medulloblastomas. High levels of dihydrolipoyl transacetylase make Group-3 medulloblastomas vulnerable to cuproptosis, a newly discovered form of copper-dependent cell death.
A new study uses explainable machine learning to predict metastasis and mortality in children with medulloblastoma, identifying key immune factors driving risk. The model provides a transparent approach to prognostic accuracy and supports personalized clinical decision-making.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
University of Oklahoma researchers discovered ZIP4 protein drives glioblastoma progression through extracellular vesicles and reprogrammed microglial plasticity. The study identifies ZIP4 and TREM1 as promising therapeutic targets for treating aggressive brain cancer.
Researchers investigated the clinical outcomes of concurrent TTFields therapy with CRT in patients with newly diagnosed glioblastoma, finding no significant difference in survival outcomes compared to adjuvant therapy. The study also showed comparable safety profiles for both treatment groups.
A new AI tool has been developed to predict the relapse of pediatric brain cancer with high accuracy, using temporal learning algorithms to analyze sequential brain scans. The tool achieved an accuracy of 75-89% in predicting recurrence, outperforming predictions based on single images.
A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.
Researchers at Dana-Farber Cancer Institute have identified a potential targeted therapy, avapritinib, for pediatric high-grade gliomas. The treatment resulted in tumor reduction and clinical improvement in 3 out of 7 patients with this currently incurable form of brain cancer.
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers at Broad Institute of MIT and Harvard have identified four coordinated gene expression programs in immune cells from glioma tumors that can lead to immunotherapy resistance. The study found two programs that could be targeted to improve patient response to immunotherapies, including one that may reduce the effectiveness of ...
A new study finds that dexamethasone, a commonly prescribed anti-swelling drug, can significantly reduce the body's immune response to brain cancer for weeks after its last dose. This effect is stronger with higher dosages and may impact immunotherapy treatments.
Researchers at Tel Aviv University have developed a novel method to measure PTEN gene activity, which is associated with cancer and autism. This breakthrough may lead to personalized therapeutics and earlier disease detection.
Researchers developed Ultra-Rapid droplet digital PCR to quickly identify genetic mutations in brain tumors, enabling accurate removal during surgery. The tool can detect small numbers of cancer cells and has the potential to become a practical tool for real-time detection during brain surgery.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Researchers at Rice University's Synthesis X Center and MD Anderson Cancer Center are developing a light-induced brain delivery platform to improve drug delivery across the blood-brain barrier for treating brain metastasis. The goal is to enhance survival rates and transform the standard of care for this deadly form of cancer.